Arcus Biosciences RCUS Remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied

Remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied at other companies

Arthur J. GallagherAJG

$986M—

L3Harris TechnologiesLHX

$40.7B+22.6%

MSCIMSCI

$1.17B+23.0%

Williams CompaniesWMB

$1.11B+5.7%

Rockwell AutomationROK

$1.36B-0.2%

Phillips 66PSX

$819M+41.5%

Other financials

Income statement

See full

Revenue$17.0M-39.3%

Operating income-$134.0M-9.8%

Net income-$128.0M-14.3%

EPS (diluted)-$1.02+10.5%

Balance sheet

See full

Cash & equivalents$201.0M+4.7%

Total debt$113.0M+88.3%

Total equity$524.0M-1.3%

Total assets$997.0M-13.8%

Cash flow

See full

Operating cash flow-$138.0M-4.5%

CapEx--100%

Free cash flow-$138.0M-3.8%

Valuation

See full

Market cap$3.62B+226%

Enterprise value$3.53B+275%

P/S15.4×+7.5×

Profitability

See full

Operating margin-168.6%-52.7pp

Net margin-156.4%-47.5pp

FCF margin-207.2%—

Returns & leverage

See full

Return on equity-70%+8.4pp

Debt / equity0.2×+0.1×

Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.

The official record: Arcus Biosciences’s 10-Q, filed October 28, 2025, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arcus Biosciences's remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied?: Arcus Biosciences (RCUS) reported remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied of $256M in Q3 2025.